Michael Flanagan

Abstract This presentation will provide an overview of the design, emergency procurement, and construction of the SR 56 Slide Repair outside of Madison. Despite being planned for the November 2025 letting, this 300-foot-long slide site adjacent to the Ohio River was successfully repaired. In March 2025, slide movement accelerated and SR 56 was closed. The emergency construction contract utilized Stage 3 plans to procure a design-build soil nail wall. We will also discuss how environmental and permit documents were updated for the 600-foot-long repair.

Avalo Therapeutics tossed its hat in the quickly evolving hidradenitis suppurative (HS) ring this week with top-line findings from the Phase II

Efforts to harness transient receptor potential melastatin (TRPM) channels to treat acute migraine have foundered, in part because their ubiquitous

Biogen top-lined results from the much-anticipated Phase II CELIA trial in which diranersen (previously BIIB080) did not improve the Clinical Dementia

Ivonescimab from Akeso and Summit Therapeutics is among the most closely watched non-GLP-1 therapies in biopharma thanks to early clinical data, most

Roche received US approval for Tecentriq (atezolizumab) and its subcutaneous Hybreza formulation as adjuvant treatment for muscle-invasive bladder

FirstWord hosted an expert call this week with Lyudmila Bazhenova — a medical oncologist and professor of medicine at University of California San Diego Moores Cancer Center — to discuss an interim Phase III HARMONi-3 analysis for ivonescimab from Akeso and Summit Therapeutics in squamous non–small-cell lung cancer (NSCLC), and it suggests about the prospects for anti-PD-1/VEGF bispecific antibodies to treat lung cancer.

A number of companies are investigating the concept of combining biologics to boost efficacy in inflammatory bowel disease (IBD), and Johnson & Johnson

The tussle among anti-PD-1/VEGF bispecifics is heating up as Bristol Myers Squibb and BioNTech's pumitamig is putting pressure on Summit Therapeutics

Chronic hepatitis B virus (HBV) infection has been an exceedingly tough nut to crack but detailed data from the Phase III B-Well trials suggest that